JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
Fiche publication
Date publication
septembre 2019
Journal
Autoimmunity reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine
Tous les auteurs :
Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P
Lien Pubmed
Résumé
Cytokines play a central role in the pathophysiology of autoimmune and inflammatory diseases. Several cytokines signal through the JAK-STAT pathway, which is now recognized as a major target to inhibit the effect of a wide array of cytokines. JAK inhibitors are increasingly used in the setting of inflammatory and autoimmune diseases. While the currently approved drugs are panJAK inhibitors, more selective small molecules are being developed and tested in various rheumatic disorders. In this extensive review, we present evidence- or hypothesis-based perspectives for these drugs in various rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, and autoinflammatory diseases.
Mots clés
Autoimmune disease, JAK inhibitor, Psoriatic arthritis, Rheumatoid arthritis, Tofacitinib
Référence
Autoimmun Rev. 2019 Sep 11;:102390